Skip to main content
☩ AI Health Guide
Menu
Affiliate disclosure: This page contains affiliate links marked with ↗. If you sign up through one of these links, we earn a commission at no extra cost to you. Our rankings and reviews are editorially independent — affiliate relationships do not influence them. Health claims have not been verified by the FDA. Read our methodology →
Last Updated:

OpenEvidence Review 2026: Free AI Medical Reference for Clinicians

A

AI Health Apps Editorial Team

Editorial Team, AI Health Guide

Updated

Reviewed against our methodology

About the editorial team  ·  Report an error

Verdict

OpenEvidence is the strongest free AI-powered medical literature search tool for clinicians as of 2026. Founded by Daniel Nadler (also founder of Kensho), OpenEvidence uses LLM reasoning over a curated peer-reviewed medical literature corpus including NEJM and other major journal partnerships. It is free for verified clinicians, has demonstrated rapid adoption in US medical schools and residency programs, and is one of the few clinical AI tools that has successfully navigated the "free for clinicians, monetised differently" model.

OpenEvidence answers "what does the recent evidence say about X?" better than any other tool we've evaluated — including general-purpose LLMs (which can be confidently wrong on clinical specifics) and traditional reference tools like UpToDate (which excel at curated comprehensive content but lack OpenEvidence's literature-search-with-AI-synthesis layer).

Pricing

OpenEvidence is free for verified clinicians (physicians, residents, medical students, nurse practitioners, physician assistants, and other licensed clinical providers). Verification is via NPI lookup or institutional email. The platform is monetised through pharma-industry partnerships and enterprise health-system deployments rather than per-clinician subscriptions.

For non-clinicians (patients, journalists, researchers), OpenEvidence is generally not available — the platform is gated to clinical users to maintain its clinician-focused content quality and tone.

Strengths

  • Genuinely free for clinicians. No paid tier for individual clinicians. Verification is fast (NPI or institutional email).
  • NEJM partnership. OpenEvidence has a content partnership with NEJM, including direct access to NEJM-published evidence with appropriate attribution and citation. This is a meaningful differentiator — most AI clinical tools don't have explicit publisher partnerships.
  • Strong literature synthesis. Output is well-organised, source-cited, and reads like a clinical literature review rather than a general-purpose LLM response. Includes effect sizes, study quality assessment, and discriminating findings.
  • Rapid clinical adoption. OpenEvidence has been adopted at multiple US medical schools and residency programs as a learning tool. Word-of-mouth among residents and medical students has been the primary growth driver.
  • Mobile-first and fast. The mobile app is well-designed for in-clinic use; query response is typically under 10 seconds.

Weaknesses

  • Not a medical device. Like Glass Health and most clinical AI tools, OpenEvidence is decision-support, not diagnostic. It does not have FDA clearance and should not be used as the sole basis for clinical decisions.
  • Pharma-industry-monetised. The free-for-clinicians model is funded in part by pharmaceutical industry partnerships. Some clinicians have raised concerns about potential bias toward pharma-favourable framing in tool output. As of May 2026, no documented systematic bias has been published, but the funding model is worth knowing.
  • Less reasoning-deep than Glass Health. OpenEvidence excels at literature search and synthesis ("what does the evidence say about treatment X?"). Glass Health is stronger at differential-diagnosis reasoning ("what could be wrong with this patient?"). The tools are complementary.
  • Coverage gaps. Despite the NEJM partnership, OpenEvidence's coverage is broader than it is deep in some clinical areas. Niche specialties or rare conditions may have thinner coverage than UpToDate or specialty-specific references.
  • Verification gates non-clinical users. Patients, journalists, researchers, and other non-clinical users are not able to use OpenEvidence. For non-clinicians wanting to research medical literature, traditional PubMed and Google Scholar remain the entry points.

OpenEvidence vs Glass Health vs UpToDate

  • OpenEvidence — AI-powered peer-reviewed literature search. Best for "what does the recent evidence say?" Free for clinicians.
  • Glass Health — AI-reasoning differential diagnosis. Best for "what could be wrong with this patient?" Has free tier and paid upgrade.
  • UpToDate — curated comprehensive clinical reference (not primarily AI). Best for deep-dive review of established clinical topics. Subscription required.

Most clinicians who use AI clinical tools end up using OpenEvidence and Glass Health together, with UpToDate as the deep-dive reference for established protocols. None replaces clinical judgement.

Pharma-funding caveat

OpenEvidence's free-for-clinicians model is partially funded by pharmaceutical industry partnerships. We mention this for transparency. As of May 2026, no published evidence indicates systematic bias in OpenEvidence output toward pharma-favourable conclusions, but the funding model is a known structural feature. Clinicians should consume OpenEvidence output with the same critical lens applied to any pharma-adjacent resource — verify against multiple sources for high-stakes decisions, particularly around drug efficacy claims and head-to-head comparisons.

Bottom line

OpenEvidence is one of the best free clinical AI tools available in 2026 and the strongest single tool for AI-powered peer-reviewed literature search. For verified clinicians, it should be on the home screen. For physicians and residents using AI clinical reasoning daily, OpenEvidence + Glass Health + UpToDate cover most use cases. The pharma-industry funding model is worth knowing about but has not produced documented bias as of this writing. None of these tools replaces clinical judgement.

Frequently asked questions

Is OpenEvidence really free?
Yes — OpenEvidence is free for verified clinicians (physicians, residents, medical students, nurse practitioners, physician assistants, other licensed clinical providers). Verification is via NPI lookup or institutional email. The platform monetises through pharma-industry partnerships and enterprise deployments rather than per-clinician subscriptions.
OpenEvidence vs Glass Health — which is better?
They serve different purposes. OpenEvidence excels at AI-powered peer-reviewed literature search ("what does the evidence say about treatment X?"). Glass Health excels at AI-reasoning differential diagnosis ("what could be wrong with this patient?"). Many clinicians use both. OpenEvidence is free; Glass has a free tier and paid upgrade.
Can patients use OpenEvidence?
Generally no. OpenEvidence is gated to verified clinicians via NPI or institutional-email verification to maintain its clinical-language output. Patients seeking medical information should use traditional resources (Mayo Clinic, NIH, peer-reviewed Google Scholar) or AI symptom-checkers like Ada Health.
Is OpenEvidence FDA-cleared?
No. OpenEvidence is positioned as clinical decision support, not diagnostic AI, and does not require FDA clearance under current guidance. Clinicians remain liable for clinical decisions.
Does OpenEvidence have an NEJM partnership?
Yes. OpenEvidence has a content partnership with the New England Journal of Medicine, including access to NEJM-published evidence with appropriate attribution and citation. This is a differentiator — most AI clinical tools don't have explicit publisher partnerships at this level.
Is OpenEvidence biased toward pharma?
OpenEvidence's free-for-clinicians model is partially funded by pharmaceutical industry partnerships. As of May 2026, no published evidence indicates systematic bias in OpenEvidence output toward pharma-favourable conclusions, but the funding model is worth knowing. Clinicians should consume output with the same critical lens applied to any pharma-adjacent resource — verify against multiple sources for drug-efficacy or head-to-head claims.
For Clinicians: Freed Try Freed ↗